Vistra Announces New Chief Executive Officer and Chief Financial Officer Appointments
Vistra, a leading global trust, fund administration and corporate services provider, today announced the appointment of Alan Brown as Group Chief Executive Officer (CEO) and Geoff Weir as Group Chief Financial Officer (CFO). Alan and Geoff will join Vistra in April.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190305005391/en/
Alan Brown, Group Chief Executive Officer, Vistra. (Photo: Business Wire)
Based in Vistra’s headquarters in Hong Kong, both Alan and Geoff will also join the company’s Board. Their appointments are subject to regulatory approval. Simon Hinshelwood, who has been leading the business as the Executive Chairman, will resume his Non-Executive Chairman role on the Board.
Alan has extensive experience in leading global organisations, in particular, businesses going through significant transformations. He has worked across a number of industries and has lived and worked in the UK, Europe, and Asia – with particularly strong China experience.
He was most recently CEO of ASCO Group – an Aberdeen, Scotland headquartered global oil and gas services company. Prior to this, Alan held the CEO position at Rentokil Initial and was CFO at Imperial Chemical Industries (which was acquired by Akzo Nobel in 2007), and spent 25 years at Unilever in various roles in the UK and Europe, before heading up Unilever’s operations in China and Taiwan.
Geoff has held a number of group CFO roles with global companies, including Scotts Philips Associates, Exridge, Digicel, and most recently Sinar Mas in Indonesia. He has extensive experience across strategy, planning, operations, M&A, compliance, and risk management in multiple sectors. He is passionate about delivering results and has had great success in driving change, accelerating growth and delivering value in complex multinational businesses.
Commenting on the appointments, Simon Hinshelwood said, “Vistra has been on a rapid growth journey, expanding from a local company operating in five markets 10 years ago, to a truly global organisation with over 4,300 employees in 46 jurisdictions. I am confident that Alan and Geoff’s strong track record and expertise will enable Vistra to achieve its continuing growth ambitions and I look forward to working with them both.”
Alan Brown said, “I am delighted to be joining Vistra with the opportunity to lead the company in the next stage of its exciting growth and transformation journey. I look forward to working with Simon, the Board, and our colleagues across the globe to maximise the opportunity the organisation has for both our clients and employees.”
About Vistra
Ranked in the top three corporate service
providers globally, Vistra is a versatile group of professionals,
providing a uniquely broad range of services and solutions. Our
capabilities span across company formations to trust, fiduciary, private
client services, and fund administration. Vistra employs over 4,300
employees across 46 jurisdictions. For more information, please visit www.vistra.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005391/en/
Contact information
Media Contact
Kate Chan, Communications Manager
media.enquiries@vistra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials, Accelerating Study Design and Execution31.10.2024 14:00:00 EET | Press release
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has introduced two new bundled offerings to meet the growing demands of oncology and vaccine research. Medidata Oncology Solutions and Medidata Vaccine Solutions reinforce the FDA guidance for patient-centered endpoints, adaptive trial designs, and trial diversity. By unifying key trial components such as real-time patient-reported outcomes and imaging management, these bundled solutions will aid sponsors by reducing trial complexity, accelerating decision-making, and improving assessments of treatment efficacy and safety. "Oncology and vaccine trials face significant challenges in recruiting diverse patients, ensuring rapid execution, and maintaining and monitoring patient safety," said Joseph Schmidt, chief operating officer, Medidata. "By making these new bundled capabilities readily available to customers, we can deliver a solution built on Medidata’s vast experience
Hassana Investment Company and EIG Sign MoU for Strategic Collaboration on Middle East Infrastructure and Energy Transition Projects31.10.2024 14:00:00 EET | Press release
Hassana Investment Company (Hassana) and EIG, a leading institutional investor to the global energy and infrastructure sectors, have signed a memorandum of understanding (MoU) to collaborate on infrastructure and energy transition projects in the Middle East through EIG’s targeted US$1 billion dedicated regional fund in which Hassana is considering becoming an anchor investor with an allocation of up to US$250 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241029142798/en/ (Photo: Business Wire) The MoU underscores EIG’s and Hassana’s shared commitment to expand their local and regional infrastructure and energy transition investment portfolios. By fostering participation from international investors and boosting foreign direct investment, this partnership aims to support the Kingdom of Saudi Arabia’s Vision 2030 goals and the broader regional shift toward cleaner, sustainable energy solutions. The MoU was signed by
Kinaxis Announces Normal Course Issuer Bid31.10.2024 13:00:00 EET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) is pleased to announce that the Toronto Stock Exchange (the “Exchange” or “TSX”) has accepted a notice (the “Notice”) filed by the Company of its intention to make a normal course issuer bid (the “NCIB”). In connection with the NCIB, the Company has entered into an automatic share purchase plan (an “ASPP”) with its designated broker to allow for purchases of its common shares (the “Shares”). The Notice provides that the Company may, during the 12-month period commencing November 6, 2024 and ending November 5, 2025, or on such earlier date as Kinaxis completes its purchases or provides notice of termination, purchase up to 1,404,639 Shares in total, representing approximately 5% of the issued and outstanding Shares as at October 23, 2024. As of the close of business on October 23, 2024, the Company had 28,092,786 Shares issued and outstanding. Except for block purchases permitted under the rules of the TSX, the number of Shares to be
Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates31.10.2024 12:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progress. “Ensuring the success of our lead COMP360 program is our absolute priority. We remain confident that COMP360 can be an effective therapy for patients with serious mental illness and our focus on delivering new treatment options for patients living with treatment-resistant depression remains paramount,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “The shift in the phase 3 pivotal program timeline has forced us to look carefully at our operations and ensure that every resource is focused on this goal. As such, we have made the difficult decision to reduce our workforce and exit activities that are not directly tied to the completion of the trials, regulatory filing and commercialization if approved. These are neces
DriveWealth Advances Global Expansion Plans with European Brokerage License from Bank of Lithuania31.10.2024 12:00:00 EET | Press release
DriveWealth, a leading financial technology platform providing Brokerage-as-a-Service, today announced that the Bank of Lithuania, the central bank of the Republic of Lithuania, granted it a brokerage license in Europe. This license accelerates DriveWealth’s international expansion and marks its third region with regulatory status, including the United States, Singapore, and now the European Economic Area. DriveWealth powers modern investing experiences, including 24-hour trading and fractional share ownership, for a community of global B2B partners. Securing this license supports DriveWealth’s ability to expand its platform to offer European securities as well as provide a “follow-the-sun” 24/7 service model continuously across time zones. The new entity in Lithuania, named DriveWealth Europe, will be an integral component of DriveWealth’s international operations and European expansion. “Achieving this license from the Bank of Lithuania marks a pivotal milestone in our global expansi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom